Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3491 - A phase I study of sonidegib (S) in combination with docetaxel (D) in patients (pts) with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study)


10 Oct 2016


Poster display


Miguel Martín


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


M. Martín1, M. Ruiz-Borrego2, J.M. Trigo Perez3, S. Antolín4, J.A. García-Sáenz5, J. Corral6, Y. Jerez7, A. Urruticoechea8, H. Colom9, N. Gonzalo10, C. Muñoz10, J. Cuevas2, C. del Monte11, L. Pérez-Ramos12, R. Caro13, A. Blach14, S. Benito11, S. Bezares Montes15, E. Carrasco16, F. Rojo17

Author affiliations

  • 1 Department Of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, 28007 - Madrid/ES
  • 2 Dept Of Oncology, Hospital Universitario Virgen del Rocio, Sevilla/ES
  • 3 Medical Oncology, Hospital Universitario Virgen de la Victoria, Malaga/ES
  • 4 Medical Oncology, Hospital Universitario a Coruna - a Corunac, A Coruna/ES
  • 5 Medical Oncology, Hospital Clinico Universitario San Carlos, Madrid/ES
  • 6 Medical Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 7 Medical Oncology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 8 Medical Oncology, Onkologikoa-Kutxaren Instituto Onkologikoa, San Sebastian/ES
  • 9 Faculty Of Pharmacy, Universitat de Barcelona, 08028 - Barcelona/ES
  • 10 Pharmacinetics Lab, Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona/ES
  • 11 Clinical Operations, GEICAM Spanish Breast Cancer Group, Madrid/ES
  • 12 Statistics, GEICAM Spanish Breast Cancer Group, Madrid/ES
  • 13 Data Management, GEICAM Spanish Breast Cancer Group, Madrid/ES
  • 14 Translational Research, GEICAM Spanish Breast Cancer Group, Madrid/ES
  • 15 Medical Lead, GEICAM Spanish Breast Cancer Group, Madrid/ES
  • 16 GEICAM (Spanish Breast Cancer Research Group), Madrid/ES
  • 17 Pathology Department, University Hospital "Fundacion Jimenez Diaz", Madrid/ES


Abstract 3491


S is a potent and selective oral inhibitor of Smo, a key component of the hedgehog (Hh) signaling pathway. Up-regulation of the Hh pathway is implicated in the genesis of a wide range of tumors including TN breast cancer. Here we report a phase I study exploring the combination of S with D in TN ABC pts to identify the Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) (ClinicalTrials.gov Identifier: NCT02027376).


Pts with ≤3 prior chemotherapy regimens for ABC were included. Treatment consisted of 21-day cycles (cy) of D 75mg/m2 on day 1, and increasing doses of S given once daily (QD). A standard 3 + 3 design was followed including 3 dose levels (DL) for S: DL1 400mg, DL2 600mg and DL3 800mg. The primary objective was to define the MTD and RP2D of the combination, based on dose-limiting toxicities (DLT) in the first 2 cy; secondary objectives included the evaluation of safety, changes on QTc, efficacy, and pharmacokinetics (PK).


12 pts were included (5 at DL1, 4 at DL2 and 3 at DL3); 3 pts were replaced due to early progressive disease (PD). Median age was 49.5 years (26–76). Pts received a median of 2 cy (2–4) at DL1, 2 cy (1–3) at DL2 and 8 cy (6–9) at DL3. No DLTs were observed in any DL. DL3 was the MTD, and toxicities grade (G) 3, none G4, in all cy included neutropenia (NP) 66.7%, CPK increase, leukopenia, and paresthesia 33.3% each; 1 event of NP and the event of CPK increase caused S dose reduction. 2 pts had G1 QTc prolongation. The mean relative dose intensity of S and D were 99.3% (94.1–100.8) and 100% (98.9-102.4), respectively. 11 pts discontinued study treatment due to PD and 1 pt by Investigator's criterion (on complete response at DL3). The objective response rate (n = 10) was 10% (95% CI 0.3-44.5). Median time to progression (n = 12) was 42.5 days (95% CI 29-155), being of 188 days at DL3. When co-administrated S and D, there was a trend to lower S trough concentrations, but could not be proved to be statistically significant and D clearance was similar on day 1 of Cycles 1 and 2.


S can be safely combined with D. Co-administration of S and D seems not to have PK interaction. S 800mg QD and D 75mg/m2 was declared as the RP2D.

Clinical trial identification

Nº EudraCT: 2013-001750-96

Legal entity responsible for the study

GEICAM (Spanish Breast Cancer Group)


Novartis Farmaceutica S.A.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings